{"id":20589,"date":"2023-01-03T17:26:21","date_gmt":"2023-01-03T11:56:21","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=20589"},"modified":"2023-01-03T17:26:24","modified_gmt":"2023-01-03T11:56:24","slug":"pharma-news-for-gilead-biogen-pfizer-ucb","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-biogen-pfizer-ucb","title":{"rendered":"Gilead Buys Out Rights to Cancer Therapy from Jounce; FDA Places Clinical Hold on Biogen\u2019s Orelabrutinib; Pfizer Announces Phase 3 BENEGENE-2 Study Result; FDA Approves MediWound\u2019s NexoBrid; UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab; FDA Approves TG Therapeutics\u2019 Briumvi"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a09950200460\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a09950200460\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-biogen-pfizer-ucb\/#Gilead_Buys_Out_Rights_to_Cancer_Therapy_from_Jounce_for_USD_67_Million\" >Gilead Buys Out Rights to Cancer Therapy from Jounce for USD 67 Million<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-biogen-pfizer-ucb\/#FDA_Places_Clinical_Hold_on_Biogens_Multiple_Sclerosis_Drug\" >FDA Places Clinical Hold on Biogen\u2019s Multiple Sclerosis Drug<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-biogen-pfizer-ucb\/#Pfizer_Announces_Positive_Top-Line_Results_from_Phase_3_Study_of_Hemophilia_B_Gene_Therapy_Candidate\" >Pfizer Announces Positive Top-Line Results from Phase 3 Study of Hemophilia B Gene Therapy Candidate<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-biogen-pfizer-ucb\/#MediWound_Announces_FDA_Approval_of_NexoBrid%C2%AE_for_the_Treatment_of_Severe_Thermal_Burns_in_Adults\" >MediWound Announces FDA Approval of NexoBrid\u00ae for the Treatment of Severe Thermal Burns in Adults<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-biogen-pfizer-ucb\/#UCB_Announces_FDA_Acceptance_of_BLA_Resubmission_for_Bimekizumab\" >UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-biogen-pfizer-ucb\/#FDA_Approves_TG_Therapeutics_Briumvi_for_Multiple_Sclerosis\" >FDA Approves TG Therapeutics\u2019 Briumvi for Multiple Sclerosis<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-gilead-buys-out-rights-to-cancer-therapy-from-jounce-for-usd-67-million\"><span class=\"ez-toc-section\" id=\"Gilead_Buys_Out_Rights_to_Cancer_Therapy_from_Jounce_for_USD_67_Million\"><\/span><strong>Gilead Buys Out Rights to Cancer Therapy from Jounce for USD 67 Million<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Gilead Sciences <\/strong>must have liked what it saw in a two-year-old collaboration with <strong>Jounce Therapeutics <\/strong>for CCR8-targeting cancer immunotherapy because the company has just agreed to own the program fully. The drug in question, <strong>GS-1811 (formerly JTX-1811),<\/strong> is an antibody drug designed to selectively deplete T regulatory cells in the tumor microenvironment that has entered phase I clinical testing for solid tumors as monotherapy and, in combination with <a href=\"https:\/\/www.delveinsight.com\/report-store\/pd-1-and-pd-l1-inhibitors-competitive-landscape\">PD-1 inhibitor<\/a> <strong>zimberelimab<\/strong>.<\/p>\n\n\n\n<p>Gilead licensed <strong>GS-1811<\/strong> in 2020 for around <strong>USD 800 million<\/strong>, including an <strong>USD 85 million<\/strong> upfront payment and a <strong>USD 35 million<\/strong> equity investment after <strong>Bristol-Myers Squibb<\/strong> returned rights to the drug, but it now wants full control and rights to the drug. To obtain it, the company will pay <strong>Jounce USD 67 million <\/strong>in exchange for foregoing up to <strong>USD 645 million<\/strong> in potential milestone payments and royalties in the high single-digit to mid-teens specified in the original agreement.<\/p>\n\n\n\n<p><strong>CCR8 <\/strong>is a chemokine receptor that is enriched on immunosuppressive tumor-infiltrating T regulatory (TITR) cells, and <strong>GS-1811<\/strong> has the potential to be the first drug in the class to reach the market, according to Gilead. Increased CCR8 expression in tumors has been linked to a poor prognosis in several types of cancer, including lung cancer, in humans.<\/p>\n\n\n\n<p>Gilead licensed the drug as part of a flurry of immuno-oncology deals that also included <strong>Arcus&#8217; zimberelimab<\/strong>, a stake in <strong>Tizona Therapeutics<\/strong>, and a broad alliance with <strong>Tango Therapeutics<\/strong>. The buyout provides Jounce with much-needed cash as it deals with recent disappointing clinical data with its lead drug candidate, ICOS agonist vopratelimab, whose future is now in doubt. <strong>Vopratelimab <\/strong>in combination with the PD-1 inhibitor <strong>pimivalimab <\/strong>failed to outperform pimivalimab alone in the <strong>phase II SELECT trial<\/strong> earlier this year, and it also failed to outperform <strong>pimivalimab <\/strong>alone in the <strong>EMERGE trial<\/strong> in 2020 in combination with <strong>BMS&#8217; CTLA4 inhibitor Yervoy (ipilimumab).<\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FDA_Places_Clinical_Hold_on_Biogens_Multiple_Sclerosis_Drug\"><\/span><strong>FDA Places Clinical Hold on Biogen\u2019s Multiple Sclerosis Drug<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Biogen&#8217;s <\/strong>efforts to replenish its multiple sclerosis pipeline have been hampered after the FDA imposed a clinical hold on a drug candidate licensed from China&#8217;s InnoCare last year for <strong>USD 125 million<\/strong> upfront. The US Food and Drug Administration has placed the oral BTK inhibitor <strong>orelabrutinib <\/strong>on partial clinical hold, which means that new patients cannot be enrolled in clinical trials, and patients who have been on the drug for 70 days or less must discontinue treatment.<\/p>\n\n\n\n<p>Those who have been taking <strong>orelabrutinib <\/strong>for at least 70 days can continue to do so. The drug is currently in a phase II trial in relapsing-remitting multiple sclerosis (RRMS), as well as early-stage studies in other autoimmune diseases. According to InnoCare, the restrictions will also apply to studies currently underway outside of the United States. The decision was motivated by a &#8220;limited number&#8221; of drug-induced liver injury cases observed in <strong>orelabrutinib <\/strong>trials. According to the study, the cases were reversible after the drug was stopped being administered, and the phase II <a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-sclerosis-market\">Multiple Sclerosis trial<\/a> is nearly complete.<\/p>\n\n\n\n<p>Liver injuries also prompted the FDA to impose a partial clinical hold on <strong>Sanofi&#8217;s BTK inhibitor tolebrutinib (SAR442168)<\/strong> earlier this year, stalling a program that was a key component of the company&#8217;s <strong>USD 3.7 billion <\/strong>acquisition of <strong>Principia Biopharma<\/strong>.&nbsp;<\/p>\n\n\n\n<p>Orelabrutinib is already approved in China as a second-line therapy for two types of blood cancer: chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) and mantle cell lymphoma (MCL). Biogen licensed rights to InnoCare&#8217;s drug in a deal worth up to <strong>USD 840 million<\/strong> after feeling the pinch with its current <a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-sclerosis-pipeline-insight\">Multiple Sclerosis drugs<\/a> such as <strong>Tecfidera (dimethyl fumarate), Avonex (interferon beta-1a), and Tysabri (natalizumab).<\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Pfizer_Announces_Positive_Top-Line_Results_from_Phase_3_Study_of_Hemophilia_B_Gene_Therapy_Candidate\"><\/span><strong>Pfizer Announces Positive Top-Line Results from Phase 3 Study of Hemophilia B Gene Therapy Candidate<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Pfizer Inc. (NYSE: PFE) announced positive top-line results from the Phase 3 BENEGENE-2 study (NCT03861273) evaluating fidanacogene elaparvovec, an investigational gene therapy for the <a href=\"https:\/\/www.delveinsight.com\/report-store\/hemophilia-b-pipeline-insight\"><strong>treatment of adult males with moderately severe to severe hemophilia B<\/strong><\/a>.<\/p>\n\n\n\n<p>Fidanacogene elaparvovec is a novel, investigational gene therapy that contains a bio-engineered AAV capsid and a high-activity human coagulation FIX gene. Once treated with Fidanacogene neparvovec, individuals with haemophilia B should be able to create FIX on their own, rather than needing to receive exogenous FIX. The BENEGENE-2 study met its primary endpoint of non-inferiority and superiority in the annualized bleeding rate (ABR) of total bleeds post-fidanacogene elaparvovec infusion versus prophylaxis regimen with Factor IX (FIX), administered as part of usual care. As per the updates from Pfizer, the key secondary endpoints showed a 78% reduction in treated ABR (p=0.0001) and a 92% reduction in annualized infusion rate (p&lt;0.0001). Through the Phase 1\/2 trials, the Fidanacogene elaparvovec was generally well-tolerated, with a safety profile.<\/p>\n\n\n\n<p>Pfizer licensed SPK-9001 (fidanacogene elaparvovec), from Spark Therapeutics pursuant to a December 2014 agreement. As per the deal, Spark Therapeutics was responsible for conducting all Phase 1\/2 studies for the investigational gene therapy, while Pfizer to look for the pivotal studies and regulatory activities. Moreover, Pfizer looks after the potential global commercialization.<\/p>\n\n\n\n<p>Hemophilia, a rare genetic bleeding disorder that causes the blood to take a long time to clot. People with hemophilia B have a deficiency in clotting FIX, a specific protein in the blood. As per the estimate, in 2021, more than 38,000 people worldwide were living with hemophilia B in 2021. As per DelveInsight, the total <a href=\"https:\/\/www.delveinsight.com\/report-store\/hemophilia-b-epidemiology-forecast\"><strong>prevalent population of Hemophilia B<\/strong><\/a> in the 7MM in 2020 was 10,739 and is expected to rise by 2032. Earlier in November 2022, the US Food and Drug Administration (FDA) approved the first gene therapy for the genetic blood-clotting disorder hemophilia B with a one-time treatment that costs US$3.5 million. The approval and the launch of Pfizer\u2019s fidanacogene elaparvovec is anticipated to further intensify the <a href=\"https:\/\/www.delveinsight.com\/report-store\/hemophilia-b-market\"><strong>hemophilia B therapeutics market<\/strong><\/a> with an alternative option for patients suffering from this rare indication.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"MediWound_Announces_FDA_Approval_of_NexoBrid%C2%AE_for_the_Treatment_of_Severe_Thermal_Burns_in_Adults\"><\/span><strong>MediWound Announces FDA Approval of NexoBrid\u00ae for the Treatment of Severe Thermal Burns in Adults<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On December 29, 2022, MediWound Ltd. (Nasdaq: MDWD) announced that the U.S. Food and Drug Administration (FDA) has approved NexoBrid\u00ae (anacaulase-bcdb) for the removal of eschar in adults with deep partial-thickness and\/or full-thickness thermal burns.&nbsp;<\/p>\n\n\n\n<p>NexoBrid (anacaulase-bcdb) is a botanical drug product containing proteolytic enzymes indicated for the removal of eschar in adults with deep partial- and\/or full-thickness thermal burns. The BLA submission leading to FDA approval covered by a comprehensive battery of pre-clinical studies and eight clinical studies, including the pivotal Phase 3 U.S. clinical study (DETECT), which evaluated the efficacy and safety of NexoBrid in <a href=\"https:\/\/www.delveinsight.com\/report-store\/burns-epidemiology-forecast\"><strong>adult patients with deep partial-thickness and full-thickness thermal burns<\/strong><\/a> of 3%-30% of total body surface area (TBSA).<\/p>\n\n\n\n<p>The study met its primary endpoint of incidence of \u226595% eschar removal compared to gel vehicle, as well as all secondary endpoints, including shorter time to eschar removal, lower incidence of surgical eschar removal, and lower blood loss compared to surgical and non-surgical standard of care (SOC), including both surgical and non-surgical eschar removal methods, with highly statistically significant results.&nbsp;<\/p>\n\n\n\n<p>NexoBrid is already approved for use in 43 countries, including the European Union, Japan, India, and other international markets. Vericel Corporation (Nasdaq: VCEL) holds an exclusive license to commercialize NexoBrid in North America. MediWound will receive a $7.5 million milestone payment from Vericel Corporation, triggered by the FDA approval of NexoBrid.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"UCB_Announces_FDA_Acceptance_of_BLA_Resubmission_for_Bimekizumab\"><\/span><strong>UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>UCB<\/strong> declared that the U.S. Food and Drug Administration has accepted for review the Biologics License Application resubmission for <strong>bimekizumab <\/strong>to treat adults with <strong>moderate to severe <\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/plaque-psoriasis-market\"><strong>plaque psoriasis<\/strong><\/a>. The resubmission was given a &#8220;<strong>Class 2<\/strong>&#8221; designation by the FDA, with a six-month evaluation period. The FDA&#8217;s response is anticipated in the second quarter of 2023.<\/p>\n\n\n\n<p>Emmanuel Caeymaex, Executive Vice President of Immunology Solutions and Head of U.S. UCB, said, &#8220;the FDA acceptance of our resubmitted application for bimekizumab is positive news that takes us one step closer to providing the first dual <strong>IL-17A<\/strong> and <strong>IL-17F inhibitor<\/strong> to fulfill the unmet needs of people suffering with moderate to severe plaque psoriasis in the United States. We will continue to work with the FDA throughout the review process to bring bimekizumab to the dermatology community in the United States as soon as possible&#8221;.<\/p>\n\n\n\n<p>In <strong>November 2022<\/strong>, UCB declared the <strong>BLA resubmission<\/strong> for bimekizumab to treat patients suffering from moderate to severe plaque psoriasis after receiving a complete response letter in May 2022.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FDA_Approves_TG_Therapeutics_Briumvi_for_Multiple_Sclerosis\"><\/span><strong>FDA Approves TG Therapeutics\u2019 Briumvi for Multiple Sclerosis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>TG Therapeutics<\/strong> announced the U.S. Food and Drug Administration had approved <strong>BRIUMVI <\/strong>for treating relapsing forms of <a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-sclerosis-market\"><strong>multiple sclerosis<\/strong><\/a>, including <a href=\"https:\/\/www.delveinsight.com\/report-store\/relapsing-remitting-multiple-sclerosis-pipeline-insight\">relapsing-remitting disease<\/a>, <a href=\"https:\/\/www.delveinsight.com\/report-store\/clinically-isolated-syndrome-cis-market\"><strong>clinically isolated syndrome<\/strong><\/a>, and <strong>active secondary progressive disease<\/strong>, in adults.&nbsp;&nbsp;<\/p>\n\n\n\n<p>Approval was granted for this disease based on data findings from the <strong>ULTIMATE I <\/strong>&amp;<strong> II Phase III trials<\/strong>, which showed superiority over <strong>teriflunomide <\/strong>in significantly reducing the annualized relapse rate, the number of <strong>T1 Gd-enhancing lesions<\/strong> and the number of <strong>new or enlarging T2 lesions<\/strong>. Results from the ULTIMATE I &amp; II trials were published in <strong>The New England Journal of Medicine<\/strong> in <strong>August 2022<\/strong>.<strong>BRIUMVI <\/strong>is the first and only <strong>anti-CD20 monoclonal antibody<\/strong> given to patients suffering from<a href=\"https:\/\/www.delveinsight.com\/report-store\/relapsing-multiple-sclerosis-rms-market\"><strong> relapsing multiple sclerosis<\/strong><\/a> that can be administered in a one-hour infusion following the starting dose.&nbsp; A <strong>150 mg infusion<\/strong> is given on <strong>day one<\/strong> over the course of four hours, a <strong>450 mg infusion<\/strong> is given on <strong>day 15<\/strong>, and then <strong>450 mg infusions<\/strong> are given every <strong>24 weeks<\/strong> over the course of an hour.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gilead Buys Out Rights to Cancer Therapy from Jounce for USD 67 Million Gilead Sciences must have liked what it saw in a two-year-old collaboration with Jounce Therapeutics for CCR8-targeting cancer immunotherapy because the company has just agreed to own the program fully. The drug in question, GS-1811 (formerly JTX-1811), is an antibody drug designed [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":20594,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":6,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[20102,830,20103,258,260,794,285,349,1497,20100,420,460,639,5789,17305,20101,2284],"industry":[17225],"therapeutic_areas":[17233,17245,17234],"class_list":["post-20589","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-bimekizumab","tag-biogen","tag-briumvi","tag-gene-therapy","tag-gene-therapy-reports","tag-gilead","tag-hemophilia-b","tag-latest-pharma-news","tag-multiple-sclerosis","tag-multiple-sclerosis-drug","tag-news","tag-pfizer","tag-pharma-news","tag-recent-pharma-news","tag-tg-therapeutics","tag-thermal-burns","tag-ucb","industry-pharmaceutical","therapeutic_areas-hematological-disorders","therapeutic_areas-neurology","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma News Updates | Gilead, Biogen, Pfizer, MediWound, UCB<\/title>\n<meta name=\"description\" content=\"Gilead-Jounce Deal, Biogen\u2019s Orelabrutinib; Pfizer&#039;s fidanacogene elaparvovec; MediWound\u2019s NexoBrid; UCB&#039;s Bimekizumab; TG\u2019s Briumvi\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-biogen-pfizer-ucb\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News Updates | Gilead, Biogen, Pfizer, MediWound, UCB\" \/>\n<meta property=\"og:description\" content=\"Gilead-Jounce Deal, Biogen\u2019s Orelabrutinib; Pfizer&#039;s fidanacogene elaparvovec; MediWound\u2019s NexoBrid; UCB&#039;s Bimekizumab; TG\u2019s Briumvi\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-biogen-pfizer-ucb\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-03T11:56:21+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-01-03T11:56:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/03172552\/Pharma-News-and-Updates-for-Gilead-Biogen-Pfizer-MediWound-UCB.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News Updates | Gilead, Biogen, Pfizer, MediWound, UCB","description":"Gilead-Jounce Deal, Biogen\u2019s Orelabrutinib; Pfizer's fidanacogene elaparvovec; MediWound\u2019s NexoBrid; UCB's Bimekizumab; TG\u2019s Briumvi","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-biogen-pfizer-ucb","og_locale":"en_US","og_type":"article","og_title":"Pharma News Updates | Gilead, Biogen, Pfizer, MediWound, UCB","og_description":"Gilead-Jounce Deal, Biogen\u2019s Orelabrutinib; Pfizer's fidanacogene elaparvovec; MediWound\u2019s NexoBrid; UCB's Bimekizumab; TG\u2019s Briumvi","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-biogen-pfizer-ucb","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2023-01-03T11:56:21+00:00","article_modified_time":"2023-01-03T11:56:24+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/03172552\/Pharma-News-and-Updates-for-Gilead-Biogen-Pfizer-MediWound-UCB.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-biogen-pfizer-ucb","url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-biogen-pfizer-ucb","name":"Pharma News Updates | Gilead, Biogen, Pfizer, MediWound, UCB","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-biogen-pfizer-ucb#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-biogen-pfizer-ucb#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/03172552\/Pharma-News-and-Updates-for-Gilead-Biogen-Pfizer-MediWound-UCB.png","datePublished":"2023-01-03T11:56:21+00:00","dateModified":"2023-01-03T11:56:24+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd"},"description":"Gilead-Jounce Deal, Biogen\u2019s Orelabrutinib; Pfizer's fidanacogene elaparvovec; MediWound\u2019s NexoBrid; UCB's Bimekizumab; TG\u2019s Briumvi","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-biogen-pfizer-ucb"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-biogen-pfizer-ucb#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/03172552\/Pharma-News-and-Updates-for-Gilead-Biogen-Pfizer-MediWound-UCB.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/03172552\/Pharma-News-and-Updates-for-Gilead-Biogen-Pfizer-MediWound-UCB.png","width":772,"height":482,"caption":"Pharma News and Updates for Gilead, Biogen, Pfizer, MediWound, UCB"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/arawat"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/03172552\/Pharma-News-and-Updates-for-Gilead-Biogen-Pfizer-MediWound-UCB-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Bimekizumab<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Biogen<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Briumvi<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Gene therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Gene Therapy Reports<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Gilead<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">hemophilia B<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Multiple Sclerosis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Multiple Sclerosis Drug<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pfizer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">TG Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Thermal Burns<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">UCB<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Bimekizumab<\/span>","<span class=\"advgb-post-tax-term\">Biogen<\/span>","<span class=\"advgb-post-tax-term\">Briumvi<\/span>","<span class=\"advgb-post-tax-term\">Gene therapy<\/span>","<span class=\"advgb-post-tax-term\">Gene Therapy Reports<\/span>","<span class=\"advgb-post-tax-term\">Gilead<\/span>","<span class=\"advgb-post-tax-term\">hemophilia B<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">Multiple Sclerosis<\/span>","<span class=\"advgb-post-tax-term\">Multiple Sclerosis Drug<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">Pfizer<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>","<span class=\"advgb-post-tax-term\">TG Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">Thermal Burns<\/span>","<span class=\"advgb-post-tax-term\">UCB<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 3 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Jan 3, 2023","modified":"Updated on Jan 3, 2023"},"absolute_dates_time":{"created":"Posted on Jan 3, 2023 5:26 pm","modified":"Updated on Jan 3, 2023 5:26 pm"},"featured_img_caption":"Pharma News and Updates for Gilead, Biogen, Pfizer, MediWound, UCB","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/20589","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=20589"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/20589\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/20594"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=20589"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=20589"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=20589"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=20589"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=20589"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}